INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 170 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2016. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $236,000 | -10.6% | 5,700 | +81.0% | 0.02% | -15.4% |
| Q2 2018 | $264,000 | -30.7% | 3,150 | 0.0% | 0.03% | -48.0% |
| Q2 2017 | $381,000 | +7.0% | 3,150 | 0.0% | 0.05% | +8.7% |
| Q1 2017 | $356,000 | +4.1% | 3,150 | 0.0% | 0.05% | +7.0% |
| Q4 2016 | $342,000 | -52.2% | 3,150 | -27.6% | 0.04% | -55.2% |
| Q3 2016 | $716,000 | +15.3% | 4,350 | 0.0% | 0.10% | +21.5% |
| Q2 2016 | $621,000 | +12.5% | 4,350 | +1.2% | 0.08% | +16.2% |
| Q1 2016 | $552,000 | -14.0% | 4,300 | 0.0% | 0.07% | -6.8% |
| Q4 2015 | $642,000 | – | 4,300 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Carmignac Gestion | 2,028,192 | $229,389,000 | 1.76% |
| Orbimed Advisors | 1,037,000 | $117,285,000 | 1.33% |
| BB BIOTECH AG | 255,719 | $28,922,000 | 0.95% |
| ALTRINSIC GLOBAL ADVISORS LLC | 193,369 | $21,870,000 | 0.74% |
| FALCON POINT CAPITAL, LLC | 44,573 | $5,041,000 | 0.67% |
| Rhenman & Partners Asset Management AB | 30,000 | $3,393,000 | 0.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 11,155 | $1,262,000 | 0.48% |
| NATIONAL PLANNING CORP | 52,400 | $5,888,000 | 0.44% |
| HIGHFIELDS CAPITAL MANAGEMENT LP | 364,232 | $41,195,000 | 0.38% |
| SPHERA FUNDS MANAGEMENT LTD. | 15,000 | $1,697,000 | 0.33% |